ADA 2025
20 - 23 June 2025
Effect of Combined Therapy with Once-Weekly Subcutaneous Cagrilintide 2.4 mg and Semaglutide 2.4 mg (CagriSema) on Energy Intake, Gastric Emptying, and Appetite in Adults with Overweight or Obesity
Affiliations
View Details
Hide Details
Keywords
Get notified when materials for ADA 2025 and future congresses become available:
Get notified when materials for ADA 2025 and future congresses become available:
Success
We will notify you when new materials become available for ADA 2025 and future congresses.
We will keep you updated in your inbox:
Almost Done